[{"orgOrder":0,"company":"RiboX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"RXRG001","moa":"","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"RiboX Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"","sponsorNew":"RiboX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"RiboX Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by RiboX Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cosmoprof
                          Not Confirmed
                          Cosmoprof
                          Not Confirmed

                          Details : RXRG001 is the first-ever circular RNA therapy candidate, which is currently being evaluated for the treatment of radiation-induced xerostomia and hyposalivation.

                          Brand Name : RXRG001

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 25, 2024

                          Lead Product(s) : RXRG001

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank